Purpose: We sought to develop a core set of clinical indicators to enable international benchmarking of localized prostate cancer management using data available in the TrueNTH Global Registry. Materials and Methods: An international expert panel completed an online survey and participated in a face-to-face meeting. Participants included 3 urologists, 3 radiation oncologists, 2 psychologists, 1 medical oncologist, 1 nurse and 1 epidemiologist with prostate cancer expertise from a total of 7 countries. Current guidelines on prostate cancer treatment and potential quality indicators were identified from a literature review. These potential indicators were refined and developed through a modified Delphi process during which each panelist independently and repeatedly rated each indicator based on importance (satisfying the indicator demonstrated a provision of high quality care) and feasibility (the likelihood that data used to construct the indicator could be collected at a population level). The main outcome measure was items with panel agreement indicated by a disagreement index less 1, median importance 8.5 or greater and median feasibility 9 or greater. Results: The expert panel endorsed 33 indicators. Seven of these 33 prostate cancer quality indicators assessed care relating to diagnosis, 7 assessed primary treatment, 1 assessed salvage treatment and 18 assessed health outcomes. Conclusions: We developed a set of quality indicators to measure prostate cancer care using numerous international evidence-based clinical guidelines. These Accepted for publication February 15, 2018. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
EVIDENCE-BASED practice, which promotes the judicious and conscientious use of scientific evidence to inform clinical management, is a pillar of modern medicine. Innumerable best practice guidelines discussing the management of localized PCa have been published, aiding practitioners to understand the most appropriate treatment in the large number of men who are diagnosed with this disease each year.
Despite the accessibility of these guidelines practice commonly varies from that recommended. For example, the rate of patients in the United States with high risk PCa who receive first line radiotherapy with concomitant ADT, which is a NCCN Ò (National Comprehensive Cancer NetworkÒ) and EAU (European Association of Urology) recommendation, ranged from 58% to 75% and was decreasing. 1 Significant discrepancies in PCa care among geographical regions have also been evidenced. 2, 3 QIs are explicitly defined, consensus based, measurable items which enable comparison and act as a catalyst for improvement. 4 Indicators are currently being used to monitor PCa quality of care by the RAND Health Science Program in the United States, 5 the NPCR (National Prostate Cancer Register) in Sweden, 6 the German Cancer Society prostate cancer centers certification program 7 and the PCOR-ANZ (Prostate Cancer Outcomes Registry in Australia and New Zealand). 8 It remains a challenge to demonstrate that outcomes in men improve as a result of performance assessment against QIs, although promising examples exist. Dissemination of benchmarking provider performance to urologists in Victoria, Australia revealed improved adherence to 3 QIs during the 5-year study period. 9 In Sweden there was improvement in 6 of 9 QIs, including the number of men with very low risk disease who underwent AS during a 3-year period. 6 The existence of numerous PCa registries and the development of international consensus minimum data sets for localized PCa by the ICHOM 10 provide an opportunity to harness existing infrastructure and investment to establish core QIs. The TrueNTH Global Registry 11 has modeled clinical and patient reported data on the ICHOM standard set for localized PCa. 10 This will provide a platform on which data can be used to evidence performance against QIs, which will be provided to participating organizations and allow comparison among peers.
The study describes an effort to identify a consensus set of QIs to benchmark PCa management among international groups contributing to the registry.
METHODS
We used a modified Delphi process, which combines scientific evidence with professional expert opinion. 12 Approval was received from the Monash University human research ethics committee (No. 2016-5551-5405).
Panel Composition and Consent Process
The panel was composed using purposive sampling of 15 international leaders of PCa research activities funded by the Movember Foundation. These invited individuals have expertise in PCa and were from countries involved in the TrueNTH Global Registry. Informed consent was obtained at project commencement.
Literature Review
A range of international guidelines for the diagnosis and management of localized PCa were reviewed, restricted to those published in English (supplementary table 1, http:// jurology.com/). We also evaluated gray literature on indicator initiatives in available PCa programs to identify potential indicators not stated in the guidelines (supplementary table 1, http://jurology.com/). These guidelines and recommendations were collated. Study investigators (FSa, JZ, LDS, JLM and SE) derived indicators from these recommendations and determined whether they could be objectively measured and developed within the limitations of the registry data set.
Online Survey
In round 1 panelists were asked to complete an online survey reviewing the refined list of proposed indicators. To maintain anonymity each participant was given an identification number which was known only by 2 of us (FSa and JZ). The indicators were presented chronologically in line with the PCa management pathway. Panelists received an accompanying document with the source of each indicator, evidence supporting strength and proposed construct (numerator and denominator). They were asked to rate the importance of each indicator on a 9-point Likert scale of 1dnot important to 9dvery important. Importance was defined as the extent to which satisfying the indicator demonstrated a provision of high quality care and conversely the extent to which not meeting the indicator signaled poor quality care. Panelists were asked to respond with "unable to comment" if they could not give an informed professional opinion. They were encouraged to suggest modifications or propose new indicators.
To establish a consistent method of measuring indicators panelists were asked to select a single risk stratification method to be used to define low, intermediate and high risk PCa.
Expert Panel Meeting
Using round 1 survey results the MI and the DI were calculated for all proposed indicators ( fig. 1 ). The MI ranged from 1 to 9. The DI is a continuous scale used to describe the dispersion of ratings by panelists (supplementary table 2, http://jurology.com/). 12 A DI of 0 represents complete agreement among panelists while a DI of 1 or greater was determined by RAND to indicate disagreement. 12 "Unable to comment" responses were excluded from calculations.
A traffic light system with the colors green, amber and red was used to differentiate among indicators with the greatest support and the greatest level of disagreement among panelists. Indicators with the greatest support, defined as a MI of 7 or greater and a DI of less than 1, were categorized as green. All indicators with panel disagreement (DI 1 or greater) were amber. Indicators with panel agreement (DI less than 1) and the lowest level of support (MI less than 7) were classified as red. Figure 1 summarizes this system.
In keeping with the RAND Delphi process 12 there was a meeting in person with an independent moderator (NSW) to discuss survey results. All indicators from round 1 were addressed with a focus on those categorized as amber (MI greater than 7 and DI 1 or greater). Following a discussion of each indicator panelists independently rerated importance and feasibility using the same 9-point Likert scale from round 1, including 1dnot important to 9dvery important and 1dnot feasible to 9ddefinitely feasible. Feasibility was defined as the likelihood that the data used to construct the indicator could be collected at a population level and be considered reliable (able to be consistently produced) and valid (measure what it ought to measure). This was completed using panelist identification numbers online or on paper depending on individual preference.
Indicator Final Review
Following the panel meeting indicators with MI 7 or greater, MF 7 or greater and DI less than 1 were presented to the panelists for review. With the final number of indicators restricted for practicality the panelists were asked to evaluate the cutoff point in terms of MI and MF for inclusion in the global registry.
RESULTS
Of the 15 invited panelists 11 (82%) accepted the invitation to participate in the study. Table 1 
<1 ≥1
There is panel agreement that the quality indicator is of low importance There is disagreement among the panel about the importance of the indicator
There is panel agreement that the quality indicator is of high importance For final review 55 indicators with MI 7 or greater, MF 7 or greater and DI less than 1 for the 2 constructs were presented to the stakeholders (table 2) . Of the 55 indicators 28 (51%) were treatment related, 18 (33%) were outcome measures and 9 (16%) concerned diagnosis. The indicator "men with high risk localized PCa do not receive AS" was removed as it was measured by "men with high risk localized PCa receive active treatment within 12 months." Three indicators, including "PSA level is taken postsurgery," "PSA level is taken post-radiotherapy" and "PSA level is taken post-ablation therapy," were merged into "PSA level is taken at 12 months after the start of active treatment." For the remaining 52 indicators the consensus was to prioritize those that were MI 8.5 or greater, MF 9 or greater and DI less than 1 for each construct (supplementary table 3 
DISCUSSION
Of the 123 indicators presented to the panel a set of 33 evidence-based and consensus based QIs were selected to initiate international PCa care benchmarking. This set of indicators addresses all major aspects of PCa management, including diagnosis, intervention and patient reported outcomes. It also identifies areas of care which are potential targets for improving service.
The pretreatment QIs that were rated high in importance and feasibility included measurement of the PSA level at diagnosis, cT documentation and the use of imaging for staging. Previous cohort studies have described unnecessary and costly routine bone scans and computerized tomography being performed in men with asymptomatic, low risk disease. 14, 15 Conversely there remains suboptimal use in men at high risk 16 despite recommendations. 13, 17 Feedback of QIs regarding the documentation of cT stage 18 and bone scans for low risk disease 19 have been shown to improve compliance with guidelines.
There was discussion among the Delphi panel on the use of multiparametric MRI for pretreatment staging. While the panel regarded digital rectal examination as the mainstay of practice, there was recognition of evidence demonstrating the superiority of multiparametric MRI to detect extracapsular extension and seminal vesicle invasion, 20 and inform treatment planning. 20, 21 However, in the absence of clear guidelines on the optimal staging protocol digital rectal examination and MRI were considered appropriate to assign a disease stage.
A treatment indicator which received the greatest support was curative treatment instigated in patients at high risk within 12 months. Although multimodality therapy is often recommended for high risk PCa, 13 ,22,23 the NPCA (National Prostate Cancer Audit) in the United Kingdom reported that 39% of men with high risk disease were under treated with ADT monotherapy. 24 Likewise the CaPSUREÔ database demonstrated that 41% of patients at high risk received ADT monotherapy. 25 No age restrictions were placed on this indicator because elderly men with good quality of life may be suitable candidates for radical treatment. 17 Men who die within 12 months of diagnosis will be excluded as they are likely unsuitable candidates for active intervention. On the contrary, the challenge faced by men with low risk disease is overtreatment and the morbidity of treatment related complications. AS has been increasingly adopted as a standard approach in these men. 6, 9 There was unanimous consensus that the number of men at low risk on AS should be reported and appropriate AS monitoring by repeat prostate biopsy or MRI within 13 months of the diagnostic biopsy should also be measured.
PSA measurement after treatment was strongly advocated as it is the primary tool to measure treatment efficacy since it detects early signs of recurrence and the need for salvage therapy. 17, 26 Other posttreatment risk assessment measures included 30-day mortality after RP, the positive margin rate after RP, and biochemical recurrence after RP and radiotherapy. Biochemical recurrence 27 was defined by our working group as PSA 0.2 ng/ml or greater after RP and a 2.0 ng/ml or greater rise above the nadir after radiotherapy. The panel did not endorse biochemical recurrence postablation therapy as an indicator due to the current lack of an agreed definition. 17, 28 Instead, the rate of men who received radical or systemic treatment 18 months after ablation therapy was nominated as a surrogate measure.
Routine collection of patient reported outcomes has been shown to improve quality of life 29 and survival, and lessen future hospitalizations. 30 In addition to EPIC-26, ICHOM recommended including question 50 on the EORTC (European Organisation for Research and Treatment of Cancer) QLQ (Quality of Life Questionnaire)-PR25 and 2 questions from the Use of Sexual Medication/Devices to improve the interpretability of the sexual function domain of the EPIC-26. 10 During the panel meeting the measurement of pretreatment and posttreatment urinary, bowel and sexual domains scores (QIs 28 to 33) were initially dropped in favor of indicators (QIs 22 to 27) assessing whether the survey instruments were administered at baseline and 12 months after treatment (supplementary  table 4 , http://jurology.com/). However, they were reinstated during the final review when it was recognized that merely collecting the EPIC-26 survey was inadequate and it was important to understand the attributes of health services for which patients reported good quality of life scores. This study has a number of notable limitations. A substantial proportion of recommendations were precluded because they could not be objectively measured or captured by the global registry data set. This most heavily impacted structural indicators such as the frequency of multidisciplinary meetings, representation of every discipline at multidisciplinary meetings and availability of specialist services, including psychological counseling and uro-oncology nurses. The use of the word offer 17, 22 in patient centered recommendations was also difficult to translate into measurable indicators. The inherent nature of the Delphi process means there is nonrandom selection of a small nonrepresentative sample of panelists. The ratings are heavily influenced by personal experience and the availability of resources at different institutions. It is acknowledged that with a different composition of panelists the final set of indicators could have been significantly altered. It is also recognized that there is a current lack of evidence demonstrating that these QIs will improve PCa specific survival.
The major strengths of this project include the heterogeneity of the panel with 11 experts from a total of 7 countries bringing important local perspectives to the discussion. The panel was facilitated by an independent and experienced moderator to mitigate the probability of conversation being dominated by a few vocal participants. Indicators were constructed based on a preexisting data set, providing the opportunity for reports to be developed immediately. This project is novel in that it allows for international benchmarking of PCa care and outcomes based on a common global data set, which can act as a stimulus to improve PCa quality of care at each contributing site.
Further effort to develop QIs which achieved a MI and a MF of 7 and 8, and to investigate other potential indicators which cannot be currently measured by items in the global registry data set will follow the initial rollout. Implemented indicators may demonstrate a ceiling effect, which would make it difficult to further improve practice. Emerging technology may also change PCa management and evolve best practice guidelines. Accordingly this set of indicators will be regularly reevaluated to ensure continued relevance and accuracy.
CONCLUSIONS
This study defined a set of 33 indicators conceived based on existing international, evidence-based clinical guidelines and endorsed by an international multidisciplinary expert panel. The indicators encompass the diagnosis, treatment and outcome aspects of PCa management. This set will be used to benchmark performance internationally to improve consistency and quality of care in men with PCa on a global basis.
